soul trial oral semaglutide cardiovascular outcomes 2024 results Canadian Perspectives 2025 Whiteboard on the Cardio-kidney-metabolic protective effects of semaglutide

NICE guidance recommends reviewing treatment after 12 weeks at the 3.0 mg maintenance dose, continuing only if at least 5% weight loss is achieved

A Study to Test Whether BI 456906 Helps Japanese People Living With Obesity Disease (SYNCHRONIZEJP)

Dietary recommendations should be adjusted based on the rate of weight reduction, nutrient status, individual tolerance, and treatment response

With an estimated $130 billion market by 2030, I believe that the market is overreacting to the current short-term issues

No, nightmares are not listed as a recognised side effect in the MHRA-approved Summary of Product Characteristics for Wegovy, nor were they identified as significant adverse events in clinical trials

It's your first line of defense